Yunxin Chen
Overview
Explore the profile of Yunxin Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
897
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Wang L, Chen Y, Yan Y, Guo X, Fang Y, Su Y, et al.
Front Oncol
. 2020 Dec;
10:585976.
PMID: 33282738
Huntingtin (HTT) is one of the target genes of miR-146-a and regulates various cancer cell activities. This study aims to explore the miR-146a expression pattern in oral squamous cell carcinoma...
32.
Fernandez de Larrea C, Staehr M, Lopez A, Ng K, Chen Y, Godfrey W, et al.
Blood Cancer Discov
. 2020 Oct;
1(2):146-154.
PMID: 33089218
CAR T-cell therapy for multiple myeloma (MM) targeting B-cell maturation antigen (; BCMA) induces high overall response rates; however, relapse occurs commonly. Implicated in relapse is a reservoir of MM...
33.
Chen Y, Nagarajan C, Tan M, Martinelli G, Cerchione C
Panminerva Med
. 2020 Sep;
63(1):28-36.
PMID: 32955181
Recent advances in treatment modalities have led to improved survival in patients with multiple myeloma (MM). However, despite these, MM remains an incurable disease. Many MM patients relapse through and...
34.
Nagarajan C, Tan M, Chen Y, Martinelli G, Cerchione C
Panminerva Med
. 2020 Sep;
62(4):225-233.
PMID: 32955180
While the outcome of patients with multiple myeloma has significantly improved over the last two decades, the disease remains incurable for the majority of patients. With the advent of novel...
35.
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz J, Purdon T, et al.
Blood Adv
. 2020 Aug;
4(15):3776-3787.
PMID: 32780846
Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-cell therapy have not been well studied. In an analysis of 83 patients with hematologic malignancies treated with CAR T-cell...
36.
Wang L, Zheng J, Pathak J, Chen Y, Liang D, Yang L, et al.
Front Cell Dev Biol
. 2020 Aug;
8:593.
PMID: 32760720
SLIT2, a member of neuronal guidance cues, has been reported to regulate inflammation and cancer progression. Periodontitis is an oral inflammatory disease that degenerates periodontal tissue, alveolar bone and tooth....
37.
Wang C, Soekojo C, De Mel S, Ooi M, Chen Y, Goh A, et al.
Cancers (Basel)
. 2020 Jul;
12(7).
PMID: 32630644
The prognosis of multiple myeloma has considerably improved due to the introduction of novel agents in the upfront setting. However, the great majority of patients ultimately relapse, and choosing a...
38.
Yeoh K, Thitsar S, Master Z, Loh Y, Chen Y, Nagarajan C, et al.
Br J Haematol
. 2020 Jun;
190(3):e160-e162.
PMID: 32519756
No abstract available.
39.
Zhong W, Li X, Pathak J, Chen L, Cao W, Zhu M, et al.
Biomater Sci
. 2020 May;
8(13):3664-3677.
PMID: 32463418
Dicalcium silicate microparticle (CS)-based biomaterials have a potential for bone and dental tissue regenerative applications. The CS-mediated transcriptome level mechanism in mesenchymal stem cells (MSCs) during bone-defect healing has not...
40.
Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, et al.
J Clin Oncol
. 2020 Mar;
38(19):2140-2150.
PMID: 32182156
Purpose: Lifirafenib is an investigational, reversible inhibitor of B-RAF, wild-type A-RAF, B-RAF, C-RAF, and EGFR. This first-in-human, phase I, dose-escalation/dose-expansion study evaluated the safety, tolerability, and efficacy of lifirafenib in...